Ensign Peak Advisors, Inc Blueprint Medicines Corp Transaction History

Ensign Peak Advisors, Inc

$51.2 Billion
Q1 2025

A detailed history of Ensign Peak Advisors, Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 303,732 shares of BPMC stock, worth $39.3 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

303,732

Previous 275,424 10.28%

Holding current value

$39.3 Million

Previous $24 Million 11.91%

% of portfolio

0.05%

Previous 0.04%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$86.69 - $115.63 $2.45 Million - $3.27 Million	28,308 Added 10.28%	303,732 $26.9 Million
Q4 2024 Feb 13, 2025	SELL	$82.48 - $101.39 $4.18 Million - $5.14 Million	-50,722 Reduced 15.55%	275,424 $24 Million
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $1.67 Million - $2.39 Million	19,830 Added 6.47%	326,146 $30.2 Million
Q2 2024 Aug 13, 2024	SELL	$85.18 - $108.78 $1.13 Million - $1.44 Million	-13,212 Reduced 4.13%	306,316 $33 Million
Q1 2024 May 14, 2024	BUY	$73.17 - $99.79 $6.91 Million - $9.42 Million	94,404 Added 41.93%	319,528 $30.3 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $8.66 Million - $18.3 Million	196,984 Added 700.01%	225,124 $20.8 Million
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $60,752 - $80,000	1,600 Added 6.03%	28,140 $1.27 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $472,190 - $764,520	11,500 Added 76.46%	26,540 $1.16 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $2.4 Million - $3.74 Million	-48,158 Reduced 76.2%	15,040 $991,000
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $335,877 - $520,933	-7,426 Reduced 10.51%	63,198 $3.19 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $152,021 - $309,324	2,810 Added 4.14%	70,624 $4.51 Million
Q4 2021 Feb 11, 2022	BUY	$94.25 - $115.99 $1.92 Million - $2.36 Million	20,368 Added 42.93%	67,814 $7.26 Million
Q3 2021 Nov 12, 2021	BUY	$80.98 - $109.47 $1.37 Million - $1.86 Million	16,953 Added 55.6%	47,446 $4.88 Million
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $82,780 - $101,000	1,000 Added 3.39%	30,493 $2.68 Million
Q1 2021 May 12, 2021	BUY	$90.71 - $108.28 $704,725 - $841,227	7,769 Added 35.76%	29,493 $2.87 Million
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $269,334 - $364,104	2,925 Added 15.56%	21,724 $2.44 Million
Q3 2020 Nov 12, 2020	SELL	$66.45 - $92.7 $64,722 - $90,289	-974 Reduced 4.93%	18,799 $1.74 Million
Q2 2020 Aug 12, 2020	SELL	$57.09 - $79.27 $137,986 - $191,595	-2,417 Reduced 10.89%	19,773 $1.54 Million
Q1 2020 May 11, 2020	SELL	$48.11 - $82.22 $30,597 - $52,291	-636 Reduced 2.79%	22,190 $1.3 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $1.52 Million - $1.89 Million	22,826 New	22,826 $1.83 Million

Others Institutions Holding BPMC

# of Institutions

379

Shares Held

67.9M

Call Options Held

1.54M

Put Options Held

1.21M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Blueprint Medicines Corp Transaction History